576 related articles for article (PubMed ID: 26939044)
1. New design of nucleotide excision repair (NER) inhibitors for combination cancer therapy.
Gentile F; Tuszynski JA; Barakat KH
J Mol Graph Model; 2016 Apr; 65():71-82. PubMed ID: 26939044
[TBL] [Abstract][Full Text] [Related]
2. Virtual screening and biological evaluation of inhibitors targeting the XPA-ERCC1 interaction.
Barakat KH; Jordheim LP; Perez-Pineiro R; Wishart D; Dumontet C; Tuszynski JA
PLoS One; 2012; 7(12):e51329. PubMed ID: 23272099
[TBL] [Abstract][Full Text] [Related]
3. Computational Characterization of Small Molecules Binding to the Human XPF Active Site and Virtual Screening to Identify Potential New DNA Repair Inhibitors Targeting the ERCC1-XPF Endonuclease.
Gentile F; Barakat KH; Tuszynski JA
Int J Mol Sci; 2018 Apr; 19(5):. PubMed ID: 29710850
[TBL] [Abstract][Full Text] [Related]
4. A truncated human xeroderma pigmentosum complementation group A protein expressed from an adenovirus sensitizes human tumor cells to ultraviolet light and cisplatin.
Rosenberg E; Taher MM; Kuemmerle NB; Farnsworth J; Valerie K
Cancer Res; 2001 Jan; 61(2):764-70. PubMed ID: 11212280
[TBL] [Abstract][Full Text] [Related]
5. XPA versus ERCC1 as chemosensitising agents to cisplatin and mitomycin C in prostate cancer cells: role of ERCC1 in homologous recombination repair.
Cummings M; Higginbottom K; McGurk CJ; Wong OG; Köberle B; Oliver RT; Masters JR
Biochem Pharmacol; 2006 Jul; 72(2):166-75. PubMed ID: 16756962
[TBL] [Abstract][Full Text] [Related]
6. Characterization of an inhibitory dynamic pharmacophore for the ERCC1-XPA interaction using a combined molecular dynamics and virtual screening approach.
Barakat KH; Torin Huzil J; Luchko T; Jordheim L; Dumontet C; Tuszynski J
J Mol Graph Model; 2009 Sep; 28(2):113-30. PubMed ID: 19473860
[TBL] [Abstract][Full Text] [Related]
7. Cell cycle checkpoint abrogator UCN-01 inhibits DNA repair: association with attenuation of the interaction of XPA and ERCC1 nucleotide excision repair proteins.
Jiang H; Yang LY
Cancer Res; 1999 Sep; 59(18):4529-34. PubMed ID: 10493501
[TBL] [Abstract][Full Text] [Related]
8. Expression of domains for protein-protein interaction of nucleotide excision repair proteins modifies cancer cell sensitivity to platinum derivatives and genomic stability.
Jordheim LP; Cros-Perrial E; Matera EL; Bouledrak K; Dumontet C
Clin Exp Pharmacol Physiol; 2014 Oct; 41(10):817-24. PubMed ID: 25115435
[TBL] [Abstract][Full Text] [Related]
9. Small Molecule Antagonists of the DNA Repair ERCC1/XPA Protein-Protein Interaction.
Obermann R; Yemane B; Jarvis C; Franco FM; Kyriukha Y; Nolan W; Gohara B; Krezel AM; Wildman SA; Janetka JW
ChemMedChem; 2024 Apr; 19(8):e202300648. PubMed ID: 38300970
[TBL] [Abstract][Full Text] [Related]
10. Functional and physical interactions between ERCC1 and MSH2 complexes for resistance to cis-diamminedichloroplatinum(II) in mammalian cells.
Lan L; Hayashi T; Rabeya RM; Nakajima S; Kanno Si; Takao M; Matsunaga T; Yoshino M; Ichikawa M; Riele Ht; Tsuchiya S; Tanaka K; Yasui A
DNA Repair (Amst); 2004 Feb; 3(2):135-43. PubMed ID: 14706347
[TBL] [Abstract][Full Text] [Related]
11. Identification of novel small molecule inhibitors of the XPA protein using in silico based screening.
Neher TM; Shuck SC; Liu JY; Zhang JT; Turchi JJ
ACS Chem Biol; 2010 Oct; 5(10):953-65. PubMed ID: 20662484
[TBL] [Abstract][Full Text] [Related]
12. Cyclosporin A inhibits nucleotide excision repair via downregulation of the xeroderma pigmentosum group A and G proteins, which is mediated by calcineurin inhibition.
Kuschal C; Thoms KM; Boeckmann L; Laspe P; Apel A; Schön MP; Emmert S
Exp Dermatol; 2011 Oct; 20(10):795-9. PubMed ID: 21707758
[TBL] [Abstract][Full Text] [Related]
13. Structural basis for the recruitment of ERCC1-XPF to nucleotide excision repair complexes by XPA.
Tsodikov OV; Ivanov D; Orelli B; Staresincic L; Shoshani I; Oberman R; Schärer OD; Wagner G; Ellenberger T
EMBO J; 2007 Nov; 26(22):4768-76. PubMed ID: 17948053
[TBL] [Abstract][Full Text] [Related]
14. The XPA-binding domain of ERCC1 is required for nucleotide excision repair but not other DNA repair pathways.
Orelli B; McClendon TB; Tsodikov OV; Ellenberger T; Niedernhofer LJ; Schärer OD
J Biol Chem; 2010 Feb; 285(6):3705-3712. PubMed ID: 19940136
[TBL] [Abstract][Full Text] [Related]
15. Conformational determinants for the recruitment of ERCC1 by XPA in the nucleotide excision repair (NER) Pathway: structure and dynamics of the XPA binding motif.
Fadda E
Biophys J; 2013 Jun; 104(11):2503-11. PubMed ID: 23746523
[TBL] [Abstract][Full Text] [Related]
16. Molecular docking and molecular dynamics study on the effect of ERCC1 deleterious polymorphisms in ERCC1-XPF heterodimer.
Priya Doss CG; Nagasundaram N
Appl Biochem Biotechnol; 2014 Feb; 172(3):1265-81. PubMed ID: 24158589
[TBL] [Abstract][Full Text] [Related]
17. Computer-aided drug design of small molecule inhibitors of the ERCC1-XPF protein-protein interaction.
Gentile F; Elmenoufy AH; Ciniero G; Jay D; Karimi-Busheri F; Barakat KH; Weinfeld M; West FG; Tuszynski JA
Chem Biol Drug Des; 2020 Apr; 95(4):460-471. PubMed ID: 31891209
[TBL] [Abstract][Full Text] [Related]
18. Metal binding mediated conformational change of XPA protein:a potential cytotoxic mechanism of nickel in the nucleotide excision repair.
Hu J; Hu Z; Zhang Y; Gou X; Mu Y; Wang L; Xie XQ
J Mol Model; 2016 Jul; 22(7):156. PubMed ID: 27307058
[TBL] [Abstract][Full Text] [Related]
19. XPA: DNA Repair Protein of Significant Clinical Importance.
Borszéková Pulzová L; Ward TA; Chovanec M
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32235701
[TBL] [Abstract][Full Text] [Related]
20. The role of conformational selection in the molecular recognition of the wild type and mutants XPA67-80 peptides by ERCC1.
Fadda E
Proteins; 2015 Jul; 83(7):1341-51. PubMed ID: 25973722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
